Path Corporation (TYO:3840)
56.00
-1.00 (-1.75%)
Aug 19, 2026, 3:30 PM JST
Path Corporation Financials Overview
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 2,358 | 2,370 | 2,253 | 2,320 | 1,991 | 2,114 |
Revenue Growth | -0.17% | 5.19% | -2.89% | 16.52% | -5.82% | -4.26% |
Gross Profit Gross Profit Growth | 1,169 | 1,157 | 1,173 | 1,101 | 971 | 1,098 |
Operating Income Operating Income Growth | -886 | -911 | -209 | -172 | -221 | -666 |
Net Income Net Income Growth | -1,231 | -1,276 | -276 | -175 | -256 | -745 |
Earnings Per Share EPS Growth | -15.51 | -16.52 | -4.35 | -3.29 | -5.46 | -20.93 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 |
Ai and Technology Business Ai and Technology Business Growth | 50.15 | 5.84 | - | - |
Beauty & Wellness Business Beauty & Wellness Business Growth | 855.97 | 1,043 | - | - |
Regenerative Medicine Related Business ( Excluding Sustainable Business) Regenerative Medicine Related Business ( Excluding Sustainable Business) Growth | 488.54 | 364.02 | 409.43 | - |
Investment Business Investment Business Growth | 40 | 12.15 | - | - |
Cosmetics Business Cosmetics Business Growth | 949.02 | 798.71 | - | - |
Unallocated Adjustment Unallocated Adjustment Growth | -23.36 | - | -0.01 | -4.72 |
Sustainable Business Sustainable Business Growth | 7.94 | 22.14 | 42.21 | - |
Market Expansion Business Market Expansion Business Growth | 1.99 | 7.6 | - | - |
Total Total Growth | 2,370 | 2,254 | 2,320 | 1,992 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 49 | 357 | 333 | 296 | 172 | 345 |
Total Debt Total Debt Growth | 50 | 250 | 292 | - | - | 500 |
Net Cash (Debt) Net Cash Growth | -1 | 107 | 41 | 296 | 172 | -155 |
Net Cash Growth | - | 160.98% | -86.15% | 72.09% | - | - |
Net Cash Per Share Net Cash Per Share Growth | -0.01 | 1.38 | 0.65 | 5.57 | 3.67 | -4.35 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | - | -435 | -538 | -76 | -352 | -835 |
Capital Expenditures CapEx Growth | - | -55 | -519 | -82 | -115 | -20 |
Free Cash Flow Free Cash Flow Growth | - | -490 | -1,057 | -158 | -467 | -855 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 49.58% | 48.82% | 52.06% | 47.46% | 48.77% | 51.94% |
Operating Margin | -37.57% | -38.44% | -9.28% | -7.41% | -11.10% | -31.50% |
Pretax Margin | -52.21% | -53.88% | -11.94% | -6.94% | -12.71% | -35.10% |
Profit Margin | -52.20% | -53.84% | -12.25% | -7.54% | -12.86% | -35.24% |
FCF Margin | - | -20.67% | -46.91% | -6.81% | -23.46% | -40.45% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 19, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PS Ratio | 1.96 | 2.34 | 3.19 | 3.88 | 1.50 | 1.12 |